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Following publication of the original article [1], the 
authors identified an error in Fig. 4. The correct Fig. 4 is 
given.
The original article has been corrected.
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Fig. 4 Effects of pitavastatin, pemafibrate or combination of pitavastatin and pemafibrate on endothelium-dependent vascular relaxations in 
response to acetylcholine. Rats were fed a normal diet (ND) or a high-salt and high-fat diet (HD). The rats were divided into five groups and treated 
with a vehicle, pitavastatin, pemafibrate (K-877), or combination of pitavastatin and pemafibrate. Data are expressed as the mean ± SD. *P < 0.001, 
HD-vehicle group versus ND-vehicle group. #P < 0.05, HD-combination group versus HD-vehicle group. Number of rats in each group: ND-vehicle, 
n = 4; HD-vehicle, n = 5; HD-pitavastatin, n = 5; HD-pemafibrate, n = 5; and HD-combination, n = 5. Statistical analysis was performed using mixed 
effect model with a Bonferroni post-hoc test
